Pharmafile

AUGUST 27, 2024

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR).

Chemotherapy 69

Chemotherapy 69

PharmExec

SEPTEMBER 18, 2024

227/KEYNOTE-483 trial, which demonstrated a 21% reduction in the risk of death when Keytruda was added to chemotherapy in patients with unresectable advanced or metastatic malignant pleural mesothelioma. Approval was based on data from the IND.227/KEYNOTE-483

Chemotherapy 52

Chemotherapy 52

RX Note

JUNE 5, 2023

Ministry of Health Systemic Therapy Protocol 2016 Ministry of Health Systemic Therapy Protocol focuses on chemotherapy and targeted therapies used in the treatment of solid tumours. However, in reality, chemotherapy regimen is not very different from how we manage a hypertension or diabetes mellitus. mg per cycle as an absolute dose.

Chemotherapy 52

Chemotherapy Diabetes Hospitals 52

STAT

SEPTEMBER 13, 2024

BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and chemotherapy improved responses for certain patients with a type of lung cancer, steering the approach into a Phase 3 study. 

Chemotherapy 286

Chemotherapy 286

European Pharmaceutical Review

JUNE 19, 2024

A non-chemotherapy multi-drug therapy enabled complete remission in 38 percent of evaluable patients with aggressive B-cell lymphoma, a Phase Ib/II clinical trial shows. The post Non-chemotherapy lymphoma treatment may provide durable remission appeared first on European Pharmaceutical Review.

Chemotherapy 98

Chemotherapy 98

Express Pharma

OCTOBER 15, 2023

Venus Remedies has received marketing approval from the Philippines, the second largest ASEAN market, for six key chemotherapy drugs. Meanwhile, the company’s oncology wing has also secured marketing approval from Myanmar for the chemotherapy drug oxaliplatin.

Chemotherapy 105

Chemotherapy 105

World Pharma News

FEBRUARY 26, 2024

Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 Lung cancer is not the most common form of cancer, but it is by far the deadliest.

Chemotherapy 86

Chemotherapy 86

Pharmacy Times

SEPTEMBER 16, 2024

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

APRIL 7, 2023

A new, sustained-release chemotherapy delivery device inserted into the bladder, facilitated tumour response, a study has reported. The intravesical device, TAR-200, provides continuous, low-dose, local delivery of gemcitabine chemotherapy. All patients had transurethral resection of bladder tumour (TURBT) to remove visible tumour.

Chemotherapy 98

Chemotherapy Mayo Clinic 98

PharmExec

AUGUST 19, 2024

The combination treatment involves administering Imfinzi with neoadjuvant chemotherapy for non-small cell lung cancer before surgery and as monotherapy post-surgery.

Chemotherapy 52

Chemotherapy 52

STAT

SEPTEMBER 13, 2024

  But she avoided digging into one particular subject: what she might have to endure with chemotherapy and radiation. When Rachel Guberman found out she had brain cancer, she did so much reading and Googling about the disease that she joked she had reached the end of the internet.  Continue to STAT+ to read the full story…

Chemotherapy 363

Chemotherapy Drug Development 363

Express Pharma

SEPTEMBER 10, 2023

Results presented from the Phase III IMpower133 study and extension trial IMbrella A, show Roche’s Tecentriq (atezolizumab), in combination with chemotherapy, demonstrates a potential long-term overall survival (OS) benefit as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). 0.91; p=0.0069). JTO Clin Res Rep.

Chemotherapy 111

Chemotherapy 111

Pharmacy Times

JUNE 17, 2024

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Business Review

JULY 8, 2024

AstraZeneca executive vice president of Oncology Business Unit Dave Fredrickson, stated, “This approval reinforces Tagrisso as the backbone therapy in EGFR-mutated lung cancer either as monotherapy or in combination with chemotherapy. Annually, there are an estimated 2.4

Chemotherapy 59

Chemotherapy 59

PharmExec

JULY 15, 2024

allows Artelo to begin a Phase I study for the drug in chemotherapy-induced peripheral neuropathy. Clearance of the New Drug Application for ART25.12

Chemotherapy 52

Chemotherapy 52

Pharmafile

MARCH 3, 2023

Scientists from the Institute of Cancer Research London, Imperial College London and the Netherlands Cancer Institute have researched a gene test which can select which advanced bowel cancer patients will respond the best to chemotherapy. read more

Chemotherapy 83

Chemotherapy Communication 83

epicur

MARCH 12, 2024

Epicur Pharma’s Advisory Council member Ann Donoghue, DVM, MS shares her personal perspective on the important relationship between veterinary oncology and compounded medications used in chemotherapy treatments. Many of the presentations discussed the chemotherapies available to treat dogs.

Compounding 52

Compounding Chemotherapy Compounding Pharmacies Labelling 52

Pharmaceutical Technology

MAY 29, 2024

A team at King’s College London has developed a “drug delivery cage” that can be filled with chemotherapy drugs.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 8 drugs in development for Chemotherapy-Induced Diarrhea (CID) by seven companies/universities/institutes. The top development phase for Chemotherapy-Induced Diarrhea (CID) is preclinical, with two drugs in that stage.

Chemotherapy 40

Chemotherapy 40

Pharmacy Times

JULY 10, 2024

Extended treatment with high doses of cisplatin-based chemotherapy is associated with severe and progressive hearing loss.

Chemotherapy 52

Chemotherapy 52

PharmaTech

JULY 2, 2024

GSK’s application for using Jemperli (dostarlimab) plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer has been accepted by the EMA.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Commerce

FEBRUARY 19, 2024

Tagrisso (osimertinib) approved for use in combination with platinum-based chemotherapy in adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.

Chemotherapy 52

Chemotherapy 52

LifeProNow

APRIL 25, 2023

The trial met its primary endpoint of investigator-assessed progression-free survival (PFS), showing a statistically significant and clinically meaningful benefit versus placebo plus chemotherapy in patients treated with dostarlimab plus carboplatin-paclitaxel in the dMMR/MSI-H population.

Chemotherapy 130

Chemotherapy 130

pharmaphorum

FEBRUARY 10, 2021

The PHERGain II study’s goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without compromising the clinical effectiveness of their treatment.

Chemotherapy 98

Chemotherapy Hospitals 98

STAT

SEPTEMBER 18, 2024

Susan underwent two lumpectomies, a mastectomy, radiation, and chemotherapy. She embarked on a challenging path of treatment, including a recurrence with stage 2 cancer four years later.

Chemotherapy 232

Chemotherapy 232

PharmExec

NOVEMBER 17, 2023

Merck's pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy approved for the first-line treatment of patients with locally advanced unresectable or metastatic, HER2-negative GEJ adenocarcinoma.

Chemotherapy 52

Chemotherapy 52

PharmExec

MARCH 7, 2024

Opdivo (nivolumab) plus cisplatin and gemcitabine was found to improve overall survival and progression-free survival compared with chemotherapy alone in patients with unresectable or metastatic urothelial carcinoma.

Chemotherapy 52

Chemotherapy 52

Pharmafile

NOVEMBER 28, 2022

South Korean biotech firm Hyundai Bioscience’s innovative chemotherapy drug may be able to complete cancer treatments in two doses. The new anticancer drug, Polytaxel, is set to enter a clinical trial on pancreatic cancer being held in Australia. read more.

Chemotherapy 78

Chemotherapy 78

PharmExec

NOVEMBER 9, 2023

Fruquintinib (Fruzaqla) is the first novel chemotherapy-free treatment option approved for metastatic colorectal cancer in more than a decade.

Chemotherapy 59

Chemotherapy 59

Pharma Times

AUGUST 16, 2024

This form of cancer was responsible for 1.9 million diagnosed cases worldwide in 2020

Chemotherapy 121

Chemotherapy 121

Pharmacy Times

APRIL 19, 2024

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

Chemotherapy 55

Chemotherapy 55

World Pharma News

MARCH 3, 2023

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the Garvan Institute of Medical Research shows.

Chemotherapy 49

Chemotherapy 49

Pharmacy Times

APRIL 25, 2024

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

Chemotherapy 48

Chemotherapy 48

Pharmaceutical Commerce

NOVEMBER 17, 2023

Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer approved by FDA after being found to lower the risk of metastasis or death.

Chemotherapy 52

Chemotherapy 52

STAT

JANUARY 22, 2024

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed. Continue to STAT+ to read the full story…

Chemotherapy 343

Chemotherapy 343

STAT

OCTOBER 21, 2023

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday. The standard treatment after surgery for these patients is chemotherapy.

Chemotherapy 354

Chemotherapy Drug Development 354

STAT

SEPTEMBER 5, 2024

For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and targeted drugs have joined or replaced older, blunter tools like chemotherapy and radiation.    Children have been less fortunate. 

Chemotherapy 314

Chemotherapy Drug Development 314